Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Accumulated Expenses (2016 - 2025)

Palisade Bio (PALI) has disclosed Accumulated Expenses for 15 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a N/A change, with the full-year FY2024 number at $1.2 million, up 59.38% from a year prior.
  • Accumulated Expenses was $1.2 million for Q3 2025 at Palisade Bio, down from $2.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.1 million in Q2 2025 to a low of $76000.0 in Q2 2022.
  • A 5-year average of $716438.4 and a median of $507500.0 in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 1295.51% in 2022, then crashed 57.41% in 2023.
  • Palisade Bio's Accumulated Expenses stood at $89000.0 in 2021, then surged by 446.07% to $486000.0 in 2022, then skyrocketed by 60.08% to $778000.0 in 2023, then soared by 59.38% to $1.2 million in 2024, then fell by 1.61% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Accumulated Expenses are $1.2 million (Q3 2025), $2.1 million (Q2 2025), and $1.2 million (Q4 2024).